Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:diseases:celiac [07.19.2019]
sallieq [Celiac disease]
home:diseases:celiac [07.20.2019] (current)
sallieq [recent research]
Line 31: Line 31:
 CONCLUSIONS:​ The mode of delivery and associated alterations in the development of the enteric homeostasis during the neonatal period might influence the incidence of celiac disease. ​ (({{pubmed>​long:​20478942}})) CONCLUSIONS:​ The mode of delivery and associated alterations in the development of the enteric homeostasis during the neonatal period might influence the incidence of celiac disease. ​ (({{pubmed>​long:​20478942}}))
 </​blockquote>​ </​blockquote>​
 +
 +The emerging data on viral and bacterial microbe-host interactions and their alterations in celiac disease provides a plausible mechanism linking environmental risk and disease development. (({{pubmed>​long:​30519552}}))
  
  
Line 66: Line 68:
 Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. ​ (({{pubmed>​long:​25023670}})) Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. ​ (({{pubmed>​long:​25023670}}))
  
-In 2015 I read that 6 individuals in the USA are currently ​suing maker of Benicar. Somewhere I saw that 1.9 million individuals are currently taking Olmesartan Medoxomil. ​ 6 in 1.9 million ? Seems pretty rare to me. (Editor)+In 2015 I saw that 6 individuals in the USA were suing maker of Benicar. ​(//​presumably for bowel immunopathology caused by cytokines//​). //Somewhere ​else found that 1.9 million individuals are currently taking Olmesartan Medoxomil.//  //6 in 1.9 million ? Seems pretty rare to me.// (//Editor//) 
 + 
 +Gluten in "​gluten-free"​ manufactured foods in Australia: a cross-sectional study. ​ (({{pubmed>​long:​30404591}})PMID 30404591 
  
 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. ​ 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. ​
home/diseases/celiac.1563572584.txt.gz · Last modified: 07.19.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.